Literature DB >> 19369251

Mode of action of cGMP-dependent protein kinase-specific inhibitors probed by photoaffinity cross-linking mass spectrometry.

Martijn W H Pinkse1, Dirk T S Rijkers, Wolfgang R Dostmann, Albert J R Heck.   

Abstract

The inhibitor peptide DT-2 (YGRKKRRQRRRPPLRKKKKKH) is the most potent and selective inhibitor of the cGMP-dependent protein kinase (PKG) known today. DT-2 is a construct of a PKG tight binding sequence (W45, LRKKKKKH, KI=0.8 microM) and a membrane translocating sequence (DT-6, YGRKKRRQRRRPP, KI=1.1 microM), that combined strongly inhibits PKG catalyzed phosphorylation (KI=12.5 nM) with approximately 1000-fold selectivity toward PKG over protein kinase A, the closest relative of PKG. However, the molecular mechanism behind this inhibition is not entirely understood. Using a combination of photoaffinity labeling, stable isotope labeling, and mass spectrometry, we have located the binding sites of PKG-specific substrate and inhibitor peptides. Covalent linkage of a PKG-specific substrate analogue was localized in the catalytic core on residues 356-372, also known as the glycine-rich loop, essential for ATP binding. By analogy, the individual inhibitor peptides W45 and DT-6 were also found to cross-link near the glycine-rich loop, suggesting these are both substrate competitive inhibitors. A bifunctional photoreactive analogue of DT-2 was found to generate dimers of PKG. This cross-linking induced covalent PKG dimerization was not observed for an N-terminal deletion mutant of PKG, which lacks the dimerization domain. In addition, non-covalent mass spectrometry was used to determine binding stoichiometry and binding order of the inhibitor peptides. Dimeric PKG binds two W45 and DT-6 peptides, whereas only one DT-2 molecule was observed to bind to the dimeric PKG. Taken together, these findings imply that (i) the two individual components making up DT-2 are both targeted against the substrate-binding site and (ii) binding of a single DT-2 molecule inactivates both PKG monomers simultaneously, which is an indication that (iii) in cGMP-activated PKG the catalytic centers of both subunits may be in each other's proximity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19369251      PMCID: PMC2713552          DOI: 10.1074/jbc.M808521200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  The effect of the source pressure on the abundance of ions of noncovalent protein assemblies in an electrospray ionization orthogonal time-of-flight instrument.

Authors:  N Tahallah; M Pinkse; C S Maier; A J Heck
Journal:  Rapid Commun Mass Spectrom       Date:  2001       Impact factor: 2.419

2.  Distinguishing among protein kinases by substrate specificities.

Authors:  N E Thomas; H N Bramson; A C Nairn; P Greengard; D C Fry; A S Mildvan; E T Kaiser
Journal:  Biochemistry       Date:  1987-07-14       Impact factor: 3.162

3.  A role for cyclic-GMP dependent protein kinase in anoikis.

Authors:  Yali Hou; Elsie Wong; Jessica Martin; Patricia V Schoenlein; Wolfgang R Dostmann; Darren D Browning
Journal:  Cell Signal       Date:  2005-08-31       Impact factor: 4.315

4.  Culture conditions influence uptake and intracellular localization of the membrane permeable cGMP-dependent protein kinase inhibitor DT-2.

Authors:  Kevin F Foley; Sergio De Frutos; Kristina E Laskovski; Werner Tegge; Wolfgang R Dostmann
Journal:  Front Biosci       Date:  2005-05-01

5.  Mass spectrometry as a novel approach to probe cooperativity in multimeric enzymatic systems.

Authors:  H Rogniaux; S Sanglier; K Strupat; S Azza; O Roitel; V Ball; D Tritsch; G Branlant; A Van Dorsselaer
Journal:  Anal Biochem       Date:  2001-04-01       Impact factor: 3.365

6.  Inhibition of cGMP-dependent protein kinase reverses phenotypic modulation of vascular smooth muscle cells.

Authors:  Nupur B Dey; Kevin F Foley; Thomas M Lincoln; Wolfgang R Dostmann
Journal:  J Cardiovasc Pharmacol       Date:  2005-05       Impact factor: 3.105

7.  Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.

Authors:  M Ploug; S Ostergaard; L B Hansen; A Holm; K Danø
Journal:  Biochemistry       Date:  1998-03-17       Impact factor: 3.162

8.  Precision substrate targeting of protein kinases. The cGMP- and cAMP-dependent protein kinases.

Authors:  J S Wood; X Yan; M Mendelow; J D Corbin; S H Francis; D S Lawrence
Journal:  J Biol Chem       Date:  1996-01-05       Impact factor: 5.157

Review 9.  Exploring the mechanisms of vascular smooth muscle tone with highly specific, membrane-permeable inhibitors of cyclic GMP-dependent protein kinase Ialpha.

Authors:  Wolfgang R G Dostmann; Werner Tegge; Ronald Frank; Christian K Nickl; Mark S Taylor; Joseph E Brayden
Journal:  Pharmacol Ther       Date:  2002 Feb-Mar       Impact factor: 12.310

10.  Zinc-induced conformational changes in the DNA-binding domain of the vitamin D receptor determined by electrospray ionization mass spectrometry.

Authors:  T D Veenstra; K L Johnson; A J Tomlinson; T A Craig; R Kumar; S Naylor
Journal:  J Am Soc Mass Spectrom       Date:  1998-01       Impact factor: 3.262

View more
  9 in total

1.  Click Chemistry Reagent for Identification of Sites of Covalent Ligand Incorporation in Integral Membrane Proteins.

Authors:  Melissa M Budelier; Wayland W L Cheng; Lucie Bergdoll; Zi-Wei Chen; Jeff Abramson; Kathiresan Krishnan; Mingxing Qian; Douglas F Covey; James W Janetka; Alex S Evers
Journal:  Anal Chem       Date:  2017-02-09       Impact factor: 6.986

2.  The oligopeptide DT-2 is a specific PKG I inhibitor only in vitro, not in living cells.

Authors:  Stepan Gambaryan; Elke Butt; Anna Kobsar; Joerg Geiger; Natalia Rukoyatkina; Rimma Parnova; Viacheslav O Nikolaev; Ulrich Walter
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

3.  17Beta-estradiol elevates cGMP and, via plasma membrane recruitment of protein kinase GIalpha, stimulates Ca2+ efflux from rat hepatocytes.

Authors:  Rebecca C Stratton; Paul E Squires; Anne K Green
Journal:  J Biol Chem       Date:  2010-06-21       Impact factor: 5.157

4.  Adenosine analogue-oligo-arginine conjugates (ARCs) serve as high-affinity inhibitors and fluorescence probes of type I cGMP-dependent protein kinase (PKGIalpha).

Authors:  Darja Lavogina; Christian K Nickl; Erki Enkvist; Gerda Raidaru; Marje Lust; Angela Vaasa; Asko Uri; Wolfgang R Dostmann
Journal:  Biochim Biophys Acta       Date:  2010-04-18

5.  Mechanistic Insights into the Hydrolysis of Organophosphorus Compounds by Paraoxonase-1: Exploring the Limits of Substrate Tolerance in a Promiscuous Enzyme.

Authors:  Sivaramakrishnan Muthukrishnan; Vivekanand S Shete; Toby T Sanan; Shubham Vyas; Shameema Oottikkal; Lauren M Porter; Thomas J Magliery; Christopher M Hadad
Journal:  J Phys Org Chem       Date:  2012-12       Impact factor: 2.391

6.  αA-crystallin-derived minichaperone stabilizes αAG98R-crystallin by affecting its zeta potential.

Authors:  Ashutosh S Phadte; Puttur Santhoshkumar; K Krishna Sharma
Journal:  Mol Vis       Date:  2018-04-11       Impact factor: 2.367

7.  An integrated workflow for crosslinking mass spectrometry.

Authors:  Marta L Mendes; Lutz Fischer; Zhuo A Chen; Marta Barbon; Francis J O'Reilly; Sven H Giese; Michael Bohlke-Schneider; Adam Belsom; Therese Dau; Colin W Combe; Martin Graham; Markus R Eisele; Wolfgang Baumeister; Christian Speck; Juri Rappsilber
Journal:  Mol Syst Biol       Date:  2019-09       Impact factor: 11.429

8.  cGMP-Dependent Protein Kinase Inhibitors in Health and Disease.

Authors:  Stefanie Wolfertstetter; Johannes P Huettner; Jens Schlossmann
Journal:  Pharmaceuticals (Basel)       Date:  2013-02-07

9.  cAMP-dependent protein kinase (PKA) complexes probed by complementary differential scanning fluorimetry and ion mobility-mass spectrometry.

Authors:  Dominic P Byrne; Matthias Vonderach; Samantha Ferries; Philip J Brownridge; Claire E Eyers; Patrick A Eyers
Journal:  Biochem J       Date:  2016-07-21       Impact factor: 3.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.